This trial is active, not recruiting.

Condition acne vulgaris
Treatments calcipotriene, placebo
Phase phase 2/phase 3
Sponsor University of California, Los Angeles
Collaborator National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Start date February 2013
End date January 2014
Trial size 54 participants
Trial identifier NCT01694433, 1 RO1 AR053542-01A2, 1R01AR053542-01A2


The purpose of this study is to study the effects of topical Vitamin D cream (Calcipotriene, also known as Dovonex) on the face and on the bacteria that cause acne. The information gained from this study may lead to new treatments for acne. In this study, Calcipotriene will be compared with a placebo, a cream that looks like Calcipotriene, but contains no active ingredients.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification efficacy study
Intervention model single group assignment
Masking double blind (subject, investigator)
Primary purpose treatment
The Calcipotriene Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
calcipotriene Dovonex
1g daily BID
(Placebo Comparator)
The Placebo Cream will be supplied as 1g daily use individual tubes to be used 2x/day (once in the morning and once in the evening) for 12 weeks.
placebo Placebo cream manufactured to mimic calcipotriene
1g daily BID

Primary Outcomes

Determine the clinical efficacy of a topical vitamin D analogue for acne therapy by assessing lesion counts (total, inflammatory and non-inflammatory)
time frame: 12 weeks

Secondary Outcomes

Clinical Global Improvement (CGI) score
time frame: 12 weeks

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: 1. Age 18 years or older, of either gender and any racial/ethnic group 2. Subjects must have clinically evident mild to moderate acne vulgaris of the facial area, IGA scale, grade 2-4 3. Subjects must understand and sign the informed consent prior to participation 4. Subjects must be in generally good health 5. Subjects must be able and willing to comply with the requirements of the protocol Exclusion Criteria: 1. Oral retinoid use within twelve months of entry into the study 2. Systemic acne therapies (oral antibiotics) within 30 days of entry into the study 3. Topical acne therapies (retinoids, antibiotics) within 14 days of entry into the study 4. Non-compliant patients 5. Pregnant or nursing women 6. Subjects with a significant medical history or concurrent condition that the investigator(s) feel is not safe for study participation 7. Subjects with hypercalcemia (hyperparathyroidism, kidney disease) 8. Subjects who cannot avoid excessive exposure to either natural or artificial sunlight.

Additional Information

Official title Innate Immunity in Acne Vulgaris
Principal investigator Jenny Kim, MD
Description This study will be a randomized, double-blinded, parallel group comparison of calcipotriene vs. placebo cream. Patients with acne will use calcipotriene or placebo cream 2x/day for 12 weeks and will be assessed at weeks 0, 2, 4, 8 and 12. Each group will have 24 subjects as calculated by power analysis. Three additional subjects for each group will be recruited for possible dropouts and total of 27 subjects will be recruited for each group. Primary endpoint (lesion count) and secondary endpoints described in aims 3.2-3.4 will be determined. Lesion counts will be assessed by one of the investigator physicians or nurse practitioner. Adverse effects including irritation, dry skin, inflammation and worsening of the lesions will be noted at each visit. Photographs will be taken to aid in assessing the clinical changes.
Trial information was received from ClinicalTrials.gov and was last updated in October 2013.
Information provided to ClinicalTrials.gov by University of California, Los Angeles.